The group's growth strategy pairs organic expansion of its seven operating businesses with disciplined, complementary acquisition. Within each division — shelter, natural biotech and food — the intent is to deepen capability, secure supply and standardise the inputs that customers depend on.

Across divisions, the group invests in shared infrastructure: governance, capital allocation, research translation and route-to-market. A particular priority is moving bioscience products from validated R&D into compliant, globally distributed formats, manufactured in Australia.

The group is privately held. Over the medium term it is building the governance, reporting and assurance maturity consistent with public-capital-markets access — strengthening board oversight, financial controls and disclosure in step with its scale.

For investor introductions, financial information requests or partnership discussions, contact the group's investor relations team.